Suppr超能文献

[医院获得性菌血症抗生素治疗的直接成本。在一家大学医院中心进行的为期6个月的前瞻性研究]

[Direct cost of antibiotic therapy prescribed for nosocomial bacteremia. Prospective study during 6 months at a CHU (University Hospital Center)].

作者信息

Daumal F, Etienne C, Votte P, Bou P, Canarelli B, Desablens F, Schmit J L, Eb F

机构信息

Unité d'Hygiène Hospitalière et Microbiologie, Hôpital Nord CHU, Amiens, France.

出版信息

Pathol Biol (Paris). 1998 Jun;46(6):470-5.

PMID:9769884
Abstract

A six-month prospective study of costs associated with antimicrobial therapy in nosocomial bacteremia was conducted from November 1, 1995 to April 30, 1996 in a 1837-bed teaching hospital, with the help of the hospital pharmacists and hospital hygiene unit. Only the costs due to the antimicrobials themselves were taken into account. A total of 238 cases of nosocomial bacteremia occurred during the study period. The total direct cost of antimicrobial therapy was 444,931 French francs (FF), i.e., 6.8% of total expenditures for antimicrobials. Mean cost per case was 1869 FF, and was 2.6-fold higher in the 21 patients with bacteremia due to more than one organism (P = 0.03). CAses with an identifiable portal of entry contributed 75% of the total cost. Portals of entry associated with the highest cost included central venous lines (103,928 FF) and urinary tract infections (50,810 FF). Although 20% of nosocomial bacteremias due to coagulase-negative staphylococci did not lead to antimicrobial therapy, the remaining 80% contributed 40.8% of the total cost, followed by nosocomial bacteremias due to Escherichia coli with 19.7% of the total cost. Thirty-seven patients (15.5%) did not receive specific antimicrobial therapy, for the following reasons: death before treatment initiation, transfer to another hospital, antimicrobial therapy initiated earlier for another infection elsewhere in the body due to a different organism, or other form of treatment. The results of this study highlight the need for prevention.

摘要

1995年11月1日至1996年4月30日,在一家拥有1837张床位的教学医院,在医院药剂师和医院卫生部门的协助下,对医院菌血症抗菌治疗相关费用进行了为期6个月的前瞻性研究。仅考虑抗菌药物本身的费用。研究期间共发生238例医院菌血症病例。抗菌治疗的总直接费用为444,931法国法郎(FF),即抗菌药物总支出的6.8%。每例平均费用为1869 FF,因一种以上病原体导致菌血症的21例患者的费用高出2.6倍(P = 0.03)。有可识别的感染入口的病例占总费用的75%。与最高费用相关的感染入口包括中心静脉导管(103,928 FF)和尿路感染(50,810 FF)。虽然20%的凝固酶阴性葡萄球菌引起的医院菌血症未导致抗菌治疗,但其余80%的病例占总费用的40.8%,其次是大肠杆菌引起的医院菌血症,占总费用的19.7%。37名患者(15.5%)未接受特异性抗菌治疗,原因如下:治疗开始前死亡、转至另一家医院、因身体其他部位的另一种病原体引起的感染而较早开始抗菌治疗或其他治疗形式。本研究结果突出了预防的必要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验